Tau Propagation Causality Test — Does Tau Spread Drive Neurodegeneration or Is It a Bystander?

Tau Propagation Causality Test

Overview

This experiment addresses the critical AD knowledge gap: "Does tau spread cause neurodegeneration or is it a bystander?" (ranked #5 in AD Knowledge Gaps with 30 points). This question determines whether anti-tau therapies will be curative or only symptomatic.

Key Question

Is the correlation between tau propagation and cognitive decline causal? Does stopping tau spread necessarily halt neurodegeneration, or can tau spread independently without causing neuronal loss?

Study Design

Rationale

If tau spread is causal: preventing propagation should halt neurodegeneration.
If tau spread is a bystander: preventing propagation may not affect outcomes — need to target upstream triggers.

Multi-arm Intervention Study

Recruit early AD patients (n=300) with varying baseline tau burden and randomize to:

| Arm | Intervention | Target |
|-----|--------------|--------|
| 1 | Anti-tau antibody (gosuranemab) | Extracellular tau clearance |
| 2 | Tau ASO (BIIB080) | Intracellular tau reduction |
| 3 | Tau aggregation inhibitor | Intracellular aggregation block |
| 4 | Standard of care | Control |

Primary Endpoints

Tau spread rate: Change in tau PET SUVR over 24 months

Neurodegeneration rate: hippocampal atrophy (MRI), FDG-PET decline

Cognitive decline: CDR, MMSE, neuropsychological battery

...

Tau Propagation Causality Test

Overview

This experiment addresses the critical AD knowledge gap: "Does tau spread cause Neurodegeneration or is it a bystander?" (ranked #5 in AD Knowledge Gaps with 30 points). This question determines whether anti-tau therapies will be curative or only symptomatic.

Key Question

Is the correlation between tau propagation and cognitive decline causal? Does stopping tau spread necessarily halt neurodegeneration, or can tau spread independently without causing neuronal loss?

Study Design

Rationale

If tau spread is causal: preventing propagation should halt neurodegeneration.
If tau spread is a bystander: preventing propagation may not affect outcomes — need to target upstream triggers.

Multi-arm Intervention Study

Recruit early AD patients (n=300) with varying baseline tau burden and randomize to:

| Arm | Intervention | Target |
|-----|--------------|--------|
| 1 | Anti-tau antibody (gosuranemab) | Extracellular tau clearance |
| 2 | Tau ASO (BIIB080) | Intracellular tau reduction |
| 3 | Tau aggregation inhibitor | Intracellular aggregation block |
| 4 | Standard of care | Control |

Primary Endpoints

Tau spread rate: Change in tau PET SUVR over 24 months

Neurodegeneration rate: hippocampal atrophy (MRI), FDG-PET decline

Cognitive decline: CDR, MMSE, neuropsychological battery

Key Analytical Approach

Test whether rate of tau propagation predicts rate of neurodegeneration within each arm:

• If causal: strong correlation maintained after intervention
• If bystander: neurodegeneration continues despite tau spread cessation

Validation Protocol

Tau Imaging

• Baseline: Tau PET (flortaucipir), Braak stage quantification
• 6-month intervals: Serial tau PET to measure propagation velocity
• Region-of-interest: entorhinal → hippocampus → temporal → parietal → frontal

Neurodegeneration Markers

• Structural: hippocampal volume, cortical thickness
• Metabolic: FDG-PET regional glucose uptake
• Fluid: NfL, p-tau181, p-tau217 trajectory

Causality Testing Framework

Granger causality: Does tau PET signal predict future neurodegeneration?

Mediation analysis: Does tau mediate amyloid → cognitive decline?

Intervention contrast: Do different mechanisms of tau reduction differ in neurodegeneration effect?

Expected Outcomes

Hypothesis 1: Tau Spread Is Causal

• Anti-tau interventions reduce both tau spread and neurodegeneration
• Correlation between tau change and neurodegeneration is maintained across arms
• Prediction: Strong correlation (r > 0.6) between tau PET change and cognitive decline

Hypothesis 2: Tau Spread Is Bystander

• Anti-tau interventions reduce tau spread but neurodegeneration continues
• Dissociation between tau change and cognitive decline
• Prediction: Weak or no correlation (r < 0.3) between tau PET change and cognitive decline

Critical Readouts

• If correlation breaks: tau is upstream trigger, not downstream effector
• If correlation persists: tau is causal driver of neurodegeneration

Feasibility Assessment

| Factor | Assessment |
|--------|------------|
| Technical Feasibility | High — tau PET, ASO, antibodies all available |
| Recruitment Feasibility | Moderate — requires early AD with low tau burden |
| Cost Estimate | $45-60M over 4 years |
| Timeline | 48 months |
| Cross-Disease Value | Critical — informs all tauopathy therapeutic strategies |

Cost Breakdown

| Component | Cost (USD) |
|-----------|------------|
| Clinical operations (4 arms, n=300) | $25M |
| Tau PET imaging (1200 scans) | $8M |
| MRI and FDG-PET | $5M |
| Biomarker assays | $4M |
| Data analysis | $3M |
| Regulatory and admin | $5M |
| Contingency (15%) | $7.5M |
| Total | $57.5M |

Risk Mitigation

• Trial duration: Use Bayesian adaptive design to detect signal at 18 months
• Dropout: Build 15% buffer, use remote monitoring
• Intervention risk: Use established agents with known safety profiles

Related Experiments

• [AD Knowledge Gaps Ranked](/gaps/ad-knowledge-gaps-ranked) — Gap #5
• [Tau Pathology Mechanisms](/mechanisms/tau-pathology)
• [Tau Propagation](/mechanisms/tau-propagation)
• [Anti-tau Immunotherapy Dosing](/experiments/anti-tau-immunotherapy-dosing)
• [Head-to-Head Anti-MTBR-Tau Antibody Comparison](/experiments/experiment-priority-index) — Rank #1

References

[Tau PET imaging in Alzheimer's disease (2024)](https://doi.org/10.1038/s41582-024-00855-0)

[Tau propagation and neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/)

[Anti-tau antibody mechanisms (2024)](https://pubmed.ncbi.nlm.nih.gov/)